Ser702
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.4
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser702  -  ARHGAP17 (human)

Site Information
LsAPRRYsssLsPIQ   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 472376

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 2 , 3 , 4 , 5 , 6 ) , mutation of modification site ( 1 ) , phospho-antibody ( 2 ) , western blotting ( 2 )
Disease tissue studied:
breast cancer ( 1 ) , acute myelogenous leukemia ( 3 )
Relevant cell line - cell type - tissue:
293 (epithelial) ( 2 ) , blood ( 3 ) , Jurkat (T lymphocyte) ( 6 ) , JY (lymphoblastoid) ( 3 ) , leukocyte-blood ( 4 ) , MO1043 (B lymphocyte) ( 5 ) , platelet-blood ( 2 ) , SUM159 (breast cell) ( 1 )

Upstream Regulation
Putative in vivo kinases:
PKACA (human) ( 2 )
Treatments:
colforsin ( 2 )

Downstream Regulation
Effects of modification on ARHGAP17:
intracellular localization ( 1 ) , molecular association, regulation ( 2 )
Induce interaction with:
FNBP1L (human) ( 2 )
Inhibit interaction with:
TRIP10 (human) ( 2 )

References 

1

Kreider-Letterman G, et al. (2023) ARHGAP17 regulates the spatiotemporal activity of Cdc42 at invadopodia. J Cell Biol 222
36571786   Curated Info

2

Nagy Z, et al. (2015) Cyclic Nucleotide-dependent Protein Kinases Target ARHGAP17 and ARHGEF6 Complexes in Platelets. J Biol Chem 290, 29974-83
26507661   Curated Info

3

Cobbold M, et al. (2013) MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia. Sci Transl Med 5, 203ra125
24048523   Curated Info

4

Raijmakers R, et al. (2010) Exploring the human leukocyte phosphoproteome using a microfluidic reversed-phase-TiO2-reversed-phase high-performance liquid chromatography phosphochip coupled to a quadrupole time-of-flight mass spectrometer. Anal Chem 82, 824-32
20058876   Curated Info

5

Goss V (2005) CST Curation Set: 940; Year: 2005; Biosample/Treatment: cell line, M01043/-; Disease: chronic lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) Akt Substrate Antibody Cat#: 9611
Curated Info

6

Rush J (2005) CST Curation Set: 710; Year: 2005; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) Akt Substrate Antibody Cat#: 9611
Curated Info